Revelation Biosciences Inc (NASDAQ: REVB) announced that a recently completed exploratory biomarker analysis confirmed clinical development plans for REVTx-300 in treating chronic kidney disease (CKD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback